E. The and . Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, pp.113-136, 2014.

H. Gelderblom, P. Hogendoorn, S. Dijkstra, C. Van-rijswijk, A. Krol et al., The Clinical Approach Towards Chondrosarcoma, The Oncologist, vol.13, issue.3, pp.320-329, 2008.
DOI : 10.1634/theoncologist.2007-0237

R. Riedel, N. Larrier, L. Dodd, D. Kirsch, S. Martinez et al., The Clinical Management of Chondrosarcoma, Current Treatment Options in Oncology, vol.93, issue.5, pp.94-106, 2009.
DOI : 10.1016/j.ijrobp.2006.08.027

J. Ivey, M. Bonakdar, A. Kanitkar, R. Davalos, and S. Verbridge, Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment, Cancer Letters, vol.380, issue.1, pp.330-339, 2016.
DOI : 10.1016/j.canlet.2015.12.019

M. Junttila and F. De-sauvage, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.37, issue.7467, pp.346-54, 2013.
DOI : 10.1038/ng1596

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

F. Chen, X. Zhuang, L. Lin, P. Yu, Y. Wang et al., New horizons in tumor microenvironment biology: challenges and opportunities, BMC Medicine, vol.23, issue.1, pp.45-12916, 2015.
DOI : 10.1097/MOU.0b013e328363de67

E. Paolicchi, F. Gemignani, M. Krstic-demonacos, S. Dedhar, L. Mutti et al., Targeting hypoxic response for cancer therapy, Oncotarget, vol.7, issue.12, pp.13464-78, 2016.
DOI : 10.18632/oncotarget.7229

R. Phillips, Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs, Cancer Chemotherapy and Pharmacology, vol.7, issue.3, pp.441-57, 2016.
DOI : 10.1002/anie.201308368

K. Ganjoo, L. Cranmer, J. Butrynski, D. Rushing, D. Adkins et al., A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma, Oncology, vol.49, issue.1-2, pp.50-56, 2011.
DOI : 10.2967/jnumed.107.045914

G. Weiss, J. Infante, E. Chiorean, M. Borad, J. Bendell et al., Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies, Clinical Cancer Research, vol.17, issue.9, pp.2997-3004, 2011.
DOI : 10.1158/1078-0432.CCR-10-3425

J. Madelmont, I. Giraud, C. Nicolas, J. Maurizis, M. Rapp et al., Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use, p.2001000621, 2001.

E. Miot-noirault, F. Gouin, A. Vidal, M. Rapp, J. Maublant et al., First Preclinical Imaging of Primary Cartilage Neoplasm and Its Local Recurrence Using, pp.99-114

C. Peyrode, V. Weber, E. David, A. Vidal, P. Auzeloux et al., Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies, Investigational New Drugs, vol.13, issue.4, pp.1782-90, 2011.
DOI : 10.1158/1078-0432.CCR-06-1696

C. Peyrode, F. Gouin, A. Vidal, P. Auzeloux, S. Besse et al., A ???Proteoglycan Targeting Strategy??? for the Scintigraphic Imaging and Monitoring of the Swarm Rat Chondrosarcoma Orthotopic Model, Sarcoma, vol.86, issue.12, pp.1-8, 2011.
DOI : 10.1186/1475-2867-10-20

E. Miot-noirault, A. Vidal, P. Auzeloux, C. Peyrode, J. Madelmont et al., In Vivo Scintigraphic Imaging of Proteoglycans, Methods Mol Biol Clifton NJ, vol.836, pp.183-98978, 2012.
DOI : 10.1007/978-1-61779-498-8_13

E. Miot-noirault, E. David, A. Vidal, C. Peyrode, S. Besse et al., 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model, EJNMMI Research, vol.3, issue.1, pp.402191-219, 2013.
DOI : 10.1016/S0720-048X(01)00427-2

URL : https://hal.archives-ouvertes.fr/inserm-00827007

J. Van-oosterwijk, J. Anninga, H. Gelderblom, A. Cleton-jansen, and J. Bovée, Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma, Hematology/Oncology Clinics of North America, vol.27, issue.5, pp.1021-1069, 2013.
DOI : 10.1016/j.hoc.2013.07.012

A. Italiano, O. Mir, A. Cioffi, E. Palmerini, S. Piperno-neumann et al., Advanced chondrosarcomas: role of chemotherapy and survival, Annals of Oncology, vol.24, issue.11, pp.2916-2938, 2013.
DOI : 10.1093/annonc/mdt374

A. Italiano, A. Cesne, C. Bellera, S. Piperno-neumann, F. Duffaud et al., GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study, Annals of Oncology, vol.24, issue.11, pp.2922-2928, 2013.
DOI : 10.1093/annonc/mdt391

O. Connor, L. Cazares-körner, C. Saha, J. Evans, C. Stratford et al., Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302), Org Chem, vol.2, pp.1026-1035, 2015.

O. Connor, L. Cazares-körner, C. Saha, J. Evans, C. Stratford et al., Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs, Nature Protocols, vol.1, issue.4, pp.781-94, 2016.
DOI : 10.1021/jm049022c

M. Hernick, C. Flader, and R. Borch, Design, Synthesis, and Biological Evaluation of Indolequinone Phosphoramidate Prodrugs Targeted to DT-diaphorase, Journal of Medicinal Chemistry, vol.45, issue.16, pp.3540-3548, 2002.
DOI : 10.1021/jm020191b

A. Angelini, G. Guerra, A. Mavrogenis, E. Pala, P. Picci et al., Clinical outcome of central conventional chondrosarcoma, Journal of Surgical Oncology, vol.19, issue.8, pp.929-966, 2012.
DOI : 10.1097/CCO.0b013e32812143d9

J. Ivey, M. Bonakdar, A. Kanitkar, R. Davalos, S. Verbridge et al., Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept, Cancer Lett. Mol Cancer Ther, vol.15, pp.2575-85, 2015.

E. Fong, S. Lamhamedi-cherradi, E. Burdett, V. Ramamoorthy, A. Lazar et al., Modeling Ewing sarcoma tumors in vitro with 3D scaffolds, Proceedings of the National Academy of Sciences, vol.6, issue.4, pp.6500-6505, 2013.
DOI : 10.1007/s12014-010-9055-y

X. Gong, C. Lin, J. Cheng, J. Su, H. Zhao et al., Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing, PLOS ONE, vol.176, issue.2, 2015.
DOI : 10.1371/journal.pone.0130348.t003

J. Sun, Q. Liu, J. Wang, D. Ahluwalia, D. Ferraro et al., Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer, Clinical Cancer Research, vol.18, issue.3, pp.758-70, 2012.
DOI : 10.1158/1078-0432.CCR-11-1980

V. Liapis, A. Labrinidis, I. Zinonos, S. Hay, V. Ponomarev et al., Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma, Cancer Letters, vol.357, issue.1, pp.160-169, 2015.
DOI : 10.1016/j.canlet.2014.11.020

J. Hu, E. Valckenborgh, D. Xu, E. Menu, H. Raeve et al., Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro, Molecular Cancer Therapeutics, vol.12, issue.9, pp.1763-73, 2013.
DOI : 10.1158/1535-7163.MCT-13-0123

J. Saggar, I. Tannock, . Jd, D. Ahluwalia, Q. Liu et al., Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy, International Journal of Cancer, vol.80, issue.11, pp.2726-2760, 2014.
DOI : 10.1159/000327739

S. Peeters, C. Zegers, R. Biemans, N. Lieuwes, R. Van-stiphout et al., TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging, Clinical Cancer Research, vol.21, issue.13, pp.2984-92, 2015.
DOI : 10.1158/1078-0432.CCR-15-0018

J. Saggar and I. Tannock, Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation -an effect that is inhibited by the hypoxiaactivated pro-drug TH-302, Clin Cancer Res, pp.2107-2121, 2015.

J. Sun, D. Ahluwalia, Q. Liu, D. Ferraro, Y. Wang et al., Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models, Cancer Biology & Therapy, vol.28, issue.15, pp.371-80, 2016.
DOI : 10.1007/s11095-009-0024-y

T. Kubo, T. Sugita, S. Shimose, T. Matsuo, K. Arihiro et al., Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours, J Bone Joint Surg Br, vol.90, pp.364-70, 2008.

A. Theocharis, S. Skandalis, G. Tzanakakis, and N. Karamanos, Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting, FEBS Journal, vol.281, issue.19, pp.3904-3927, 2010.
DOI : 10.1074/jbc.M601061200

D. Mihov and M. Spiess, Glycosaminoglycans: Sorting determinants in intracellular protein traffic, The International Journal of Biochemistry & Cell Biology, vol.68, pp.87-91, 2015.
DOI : 10.1016/j.biocel.2015.08.019

C. Voutouri and T. Stylianopoulos, Evolution of osmotic pressure in solid tumors, Journal of Biomechanics, vol.47, issue.14, pp.3441-3448, 2014.
DOI : 10.1016/j.jbiomech.2014.09.019